Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status

BACKGROUND: Poor initial response to tamoxifen due to CYP2D6 polymorphism and adverse side effects are two clinical challenges in tamoxifen therapy. We report the development and preclinical testing of a boronic prodrug to orally deliver 4-OHT at therapeutically effective concentrations but at a fra...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Qiu, Zhang, Changde, Zhang, Qiang, Miele, Lucio, Zheng, Shilong, Wang, Guangdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563833/
https://www.ncbi.nlm.nih.gov/pubmed/26354796
http://dx.doi.org/10.1186/s12885-015-1621-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563833/
https://www.ncbi.nlm.nih.gov/pubmed/26354796
http://dx.doi.org/10.1186/s12885-015-1621-2

Ejemplares similares